Compare FBK & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBK | TARS |
|---|---|---|
| Founded | 1906 | 2016 |
| Country | United States | United States |
| Employees | N/A | 370 |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2016 | 2020 |
| Metric | FBK | TARS |
|---|---|---|
| Price | $52.70 | $64.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $64.50 | ★ $89.00 |
| AVG Volume (30 Days) | 191.5K | ★ 649.2K |
| Earning Date | 04-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 1.10 | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $41.72 | $56.43 |
| Revenue Next Year | $7.21 | $30.19 |
| P/E Ratio | $46.94 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $42.29 | $38.51 |
| 52 Week High | $62.37 | $85.25 |
| Indicator | FBK | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 50.82 |
| Support Level | $52.27 | $60.38 |
| Resistance Level | $53.04 | $67.24 |
| Average True Range (ATR) | 1.10 | 3.70 |
| MACD | -0.15 | 0.30 |
| Stochastic Oscillator | 43.10 | 74.62 |
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates majority of revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.